ERBB2 and breast cancer: The persistent adverse prognostic value of elevated HER2 ECD levels in stage I/II early breast cancer could reflect the presence of micrometastases or high rates of HER2 cleavage and shedding, with the production of truncated cell-associated fragments that contain the signaling kinase domain that is activated in the absence of the ECD.